Headquartered in Branford, CT Fiscal year ends December NASDAQ: QSI quantum-si.com
Quantum-Si is a proteomics technology company developing single-molecule protein sequencing platforms for life sciences research. The company's benchtop platform enables real-time kinetic-based detection of proteins, allowing researchers to bypass traditional multistep workflows and directly access dynamic, functional protein insights. Quantum-Si currently markets its Platinum protein sequencing instruments and consumable kits while developing its next-generation Proteus platform, which is expected to launch commercially in Q2 2027. The company serves researchers across human proteomics and is expanding into non-human proteomics markets including agricultural applications, pathogen detection, and viral protein surveillance. Quantum-Si trades on the Nasdaq under the ticker QSI and has Class A and Class B common stock structures. Updated
Live Updates First earnings reaction4:30pm ETFirst reaction to QSIs earnings: 1. Product traction:Platinum Pro officially launched and shipped, but no units/revenue per customer disclosed. Adoption remains early-stage. 2. Burn rate update:Q1 net…
Joel South Quantum computing, which offers the promise of faster computational power than what’s currently available, has implications for artificial intelligence (AI) and other lucrative technology fields. It also holds the promise of potential…
One of Cathie Wood's Ark Invest funds bought over 800,000 shares of Quantum-Si on July 22.
One of Cathie Wood's Ark Invest funds bought over 280,000 shares of Quantum-Si on July 13.
One of Cathie Wood's Ark Invest funds bought over 350,000 shares of Quantum-Si on July 1.
One of Cathie Wood's Ark Invest funds bought over 460,000 shares of Quantum-Si on June 28.
Quantum-Si is a proteomics technology company developing single-molecule protein sequencing platforms for life sciences research.
The Wall Street consensus 12-month price target for QSI is $2.28.
